Targepeutics
Hershey
About Targepeutics
Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight and diagnose cancer and other diseases. Our lead compound, GB-13, is currently advancing toward a Phase I clinical trial for several cancer targets. GB-13 is a genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage. We have also licensed related technology for a cancer immunotherapy that is in Phase III clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $200.0K
- Funding stage: Seed
- Last round: Seed (Jun 2025)
- Website: targepeutics.com
- Phone: (717) 571-2402
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/targepeutics-164510 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.